Johnson & Johnson announced long-term results from the Phase 2 CARTITUDE-2 study showing that 50% of multiple myeloma patients treated early with a single CARVYKTI infusion remained alive and progression-free for at least five years without maintenance therapy. These findings suggest earlier use of CARVYKTI could improve long-term remission and disease control, potentially offering curative benefits. The safety profile remains consistent with previous studies, and the therapy continues to be evaluated in ongoing trials.
Johnson & Johnson shares show minimal movement with a 0.02% increase, trading at USD 270.74 on Pluang. As of Sep 25, 2026 18:01 WIB, the stock maintains a strong market cap of $652.31B despite a majority of Pluang users selling, with 85% sell orders and 15% buy orders.
Johnson & Johnson announced that TREMFYA (guselkumab) met primary and major secondary endpoints in the Phase 4 STAR study, showing significant improvement in axial symptoms and MRI-confirmed inflammation in biologic-naïve adults with active psoriatic...
Retirees deciding between federally insured CDs and dividend stocks must consider yield stability versus growth potential. CDs offer fixed interest rates, currently averaging 1.73% nationally, with FDIC insurance protecting principal up to $250,000. ...
Johnson & Johnson announced data from the Phase 3 MajesTEC-3 trial showing that combining TECVAYLI with DARZALEX FASPRO significantly improves survival in relapsed or refractory multiple myeloma patients. About 87% of treated patients had mortality r...
